| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status | 
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J9196 | Gemcitabine HCl (ACCORD) | Gemcitabine | 200MG | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 2011 | Mar 17, 2023 | In Use | ||
| NA | Belumosudil | Rezurock | 200mg | Chemotherapy | Rho Kinase Inhibitor | ROCK1, ROCK2 | Yes | 2021 | In Use | |||
| NA | Purixan | Purixan | 20mg | Chemotherapy | Antimetabolite | Purine | Yes | 2014 | In Use | |||
| NA | Megestrol Acetate | Megace | 20mg, 40mg | Hormonal Therapy | Progestin | Yes | 1988 | In Use | ||||
| NA | Selinexor | Xpovio | 20mg, 40mg, 50mg, 60mg | Chemotherapy | Enzyme Inhibitor | XPO1 | Yes | 2019 | In Use | |||
| Asciminib | Scemblix | 20mg,40mg | Chemotherapy | Tyrosine Kinase Inhibitor | ABL/BCR-ABL1 | Yes | 2021 | In Use | ||||
| NA | Tepotinib Hydrochloride | Tepmetko | 225mg | Chemotherapy | Tyrosine Kinase Inhibitor | MET | Yes | 2021 | In Use | |||
| NA | Vemurafenib | Zelboraf | 240 mg | Chemotherapy | Enzyme Inhibitor | BRAF | Yes | 2011 | In Use | |||
| J2354 | octreotide | sandostatin | 25 mcg | Hormonal Therapy | Somatostatin Analog | No | 1998 | Jan 1, 2004 | In Use | |||
| J2468 | Palonosetron hydrochloride (avyxa) | Palonosetron hydrochloride (avyxa) | 25 MCG | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | No | 2016 | Jun 10, 2024 | In Use | ||
| J2469 | Palonosetron | Aloxi | 25 mcg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | No | 2003 | Jan 1, 2005 | In Use | ||
| C9210 | Palonosetron | Aloxi | 25 mcg | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | No | 2003 | Jan 1, 2004 | Dec 31, 2004 | No Longer Used | |
| J9395 | Fulvestrant | Faslodex | 25 mg | Hormonal Therapy | Estrogen Receptor Antagonist | No | 2002 | Jan 1, 2004 | In Use | |||
| NA | Midostaurin | Rydapt | 25 mg | Chemotherapy | Tyrosine Kinase Inhibitor | FLT3 | Yes | 2017 | In Use | |||
| NA | Ruxolitinib | Jakafi | 25 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
| J8530 | Cyclophosphamide | Cyclophosphamide oral | 25 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Yes | 1959 | Jan 1, 1995 | In Use | ||
| NA | Erlotinib | Tarceva | 25 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2004 | In Use | |||
| S0156 | Exemestane | Aromasin | 25 mg | Hormonal Therapy | Aromatase Inhibitor | Yes | 1999 | Jan 1, 2001 | In Use | |||
| NA | Cortisone Acetate | Cortisone Acetate | 25 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | Yes | 1951 | In Use | |||
| NA | Leucovorin Calcium | Calcium leucovorin, Lederfoline, Leucosar, Leucovorin rescue, Wellcovorin | 25 mg | Ancillary Therapy | Chemoprotective | Antidote | Yes | 1952 | Jan 1, 1997 | In Use | ||
| NA | Sunitinib malate | Sutent | 25 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR,KIT, RET, CSF | Yes | 2006 | In Use | |||
| NA | Lapatinib | Tykerb | 250 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Yes | 2007 | In Use | |||
| NA | Rucaparib | Rubraca | 250 mg | Chemotherapy | Enzyme Inhibitor | PARP | Yes | 2017 | In Use | |||
| NA | Abiraterone acetate | Zytiga | 250 mg | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Yes | 2011 | In Use | |||
| J8565 | Gefitinib | Iressa | 250 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2015 | Jan 1, 2005 | In Use | 
                The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
                not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
                specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
                truly not available.
            
        
 Home